US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Biora convenes Extraordinary Shareholders' meeting

Biora convenes Extraordinary Shareholders' meeting The Board of Directors of Biora resolved to convene an Extraordinary Shareholders' Meeting on Wednesday August 6, 2003 at 1:00 pm at Medeon Science Park, Malmö, due to the accomplished change of ownership. The notice is attached hereto. Biora develops manufactures and sells biotechnology-based products to dentists. Its principal product, Emdogain®Gel, which is approved for sale in Europe, North America and Japan among others, naturally regenerates tooth-supporting structure that the tooth has lost due to periodontitis. Biora's shares are

Last trading day for Biora shares

The last trading day for Biora AB's Ordinary Shares Biora AB has applied for the de-listing of its Ordinary Shares from the Stockholm Stock Exchange (SSE). The last trading day for Biora's Ordinary Shares on the SSE will be Friday July 4th, 2003. Biora develops manufactures and sells biotechnology-based products to dentists. Its principal product, Emdogain®Gel, which is approved for sale in Europe, North America and Japan among others, naturally regenerates tooth-supporting structure that the tooth has lost due to periodontitis. Biora's shares are listed on the "O-list" of the Stockholm

Compulsory Acquisition of Biora AB

Compulsory Acquisition of Biora AB Ordinary Shares. Straumann AG Holdings ("Straumann") has announced that it has acquired approximately 91 percent of the Ordinary Shares of Biora AB pursuant to its public offer. Straumann has called for the compulsory acquisition of the remaining outstanding Biora Ordinary Shares. Accordingly, the Biora Board has decided to refer the compulsory acquisition matter to an arbitration board. The Board of Biora has also decided to submit an application for de-listing Biora's Ordinary Shares from the "O-list" of the Stockholm Stock Exchange ("SSE"). Information

New indication in the US for Biora

A new indication for EmdogainGel approved in the US Biora has received U.S. Food and Drug Administration (FDA) approval for a new indication for EmdogainGel in the treatment of mandibular Class II furcations with minimal proximal bone loss (periodontal defects between the tooth roots in the lower jaw). Biora plans to launch this new indication in the US market in June 2003. Donna Janson, CEO and President of Biora comments: "The recent FDA approval for the use of EmdogainGel in the treatment of furcations defects further demonstrates Emdogain´s regenerative ability and efficacy. Furcation

Statement from Biora Board

Statement from the Board of Biora AB regarding the offer from Straumann Holding AG. Upon a shareholder request, the Board of Biora AB will publish the fairness opinion prepared by Enskilda Securities in regards to the offer made by Straumann Holding AG for all the outstanding Biora shares (the "Offer"). The Board notes that Enskilda Securities' evaluation of the Offer also reviewed the Offer from a so-called "discounted cash-flow" analysis and concluded that the Offer is also fair from a financial standpoint pursuant to this analysis. The Board's recommendation for shareholders to accept

Biora Annual General Meeting held on April 29 in Malmö, Sweden

Biora Annual General Meeting held on April 29th in Malmö, Sweden At the Annual General Meeting "AGM" in Malmö, Sweden today, six of the ordinary members of the Board of Directors were re-elected. Jan Kvarnström, member of Biora Board since January 2002 and Lennart Jacobsson, deputy Board member declined re-election due to changed responsibilities. A new Deputy Director, Håkan Bohlin was elected. Shareholders at the Annual General meeting adopted the Board of Directors' proposal to amend the Articles of Association regarding notices of extraordinary meetings. In the future, notices will not

Report for the first quarter 2003

Report for the first quarter 2003 Biora AB (publ) April 25, 2003 1st Qtr 1st Qtr Full Year 2003 2002 2002 Net sales, SEK million 34.6 35.0 129.7 Operating result, SEK million 1.4 -1.0 -0.9 Net result, SEK million 1.4 -0.7 0.7 · On April 7, 2003, Straumann Holding AG announced a public offer to the shareholders and warrant holders of Biora AB. Biora´s Board of Directors unanimously recommends that Biora shareholders accept the cash offer of SEK 17 per ordinary share. · Sales during the first quarter 2003 amounted to SEK 34.6 million (compared to SEK 35.0 million for the first quarter 2002). ·

Change of date for release of Biora´s report for the first quarter 2003

Change of date for release of Biora´s report for the first quarter 2003. Biora´s Board of Directors have decided to release the report for the first quarter 2003 on April 25th, 2003. Biora develops manufactures and sells biotechnology-based products to dentists. Its principal product, Emdogain®Gel, which is approved for sale in Europe, North America and Japan among others, naturally regenerates tooth-supporting structure that the tooth has lost due to periodontitis. Biora's shares are listed on the "O-list" of the Stockholm Stock Exchange in Sweden. This press release may contain certain

Statement by the Board of Directors of Biora AB regarding Straumann Holding AG´s offer

Statement by the Board of Directors of Biora AB regarding Straumann Holding AG's offer In a press release today, Straumann Holding AG ("Straumann") announced the following public offer to the shareholders of and the holders of warrants issued by Biora AB ("Biora"): · SEK 17 per ordinary share of Biora; · SEK 1.50 for each warrant 2001/2004 issued by Biora. The Board of Directors of Biora (the "Board") has retained Enskilda Securities to evaluate the offer. Enskilda Securities has come to the conclusion that the offer is fair from a financial point of view. The offer by Straumann of SEK 17

Medpharma plc agrees to further development with Biora AB

Medpharma plc agrees to further development with Biora Biora AB and Medpharma plc (UK) have reached a settlement concerning their dispute regarding their license agreement for development and commercialization of the Xerostomia (dry mouth) project. Medpharma has also committed to further developing with Biora, the Xerostomia product through phase II clinical trials. Biora AB has received $50,000 as a part payment for license fees due under the license agreement with Medpharma plc. Biora´s claim on Medpharma for license fees due still amounts to approximately USD 450,000, which Medpharma has

Biora terminates its License Agreement with Medpharma

Biora terminates its License Agreement with Medpharma plc Following the non-payment by Medpharma plc (UK) of license fees due to Biora in the first quarter of 2003, the Company has decided to terminate its license agreement with Medpharma for the xerostomia (dry mouth) project targeted to groups other than dentists and dental specialists. Biora has a claim against Medpharma for the unpaid license fees in the amount of USD 500,000 plus interest. This amount has not been accounted in previous reporting periods. In addition, Biora may be entitled to additional damages. Biora has not yet

Changes to Biora´s Board of Directors

Changes to Biora´s Board of Directors The Biora Board was advised today that at the company´s Annual General Meeting on April 29, 2003, Jan Kvarnström and Lennart Jacobsson will decline to seek re-election as Directors. Jan Kvarnström has been a member of the Board since January 2002 and Lennart Jacobsson has been the deputy Board member since 1987. Both directors are declining re-election to Biora´s Board due to their increasing workload. Due to the Company´s current strategy and the broad experience of the other six Directors on the Biora Board, there are no plans to nominate new

Biora Year-End Report 2002

Year End Report 2002 Biora AB (publ) February 13, 2003 4th Qtr 4th Qtr Full Year Full Year 2002 2001 2002 2001 Net sales, SEK million 30.2 32.9 129.7 110.7 Operating result, SEK million 0.5 0.2 -0.9 -26.5 Net result, SEK million 1.2 0.6 0.7 -25.1 · Net result for 2002 was a profit of SEK 0.7 million (compared to a net loss of SEK 25.1 million for 2001). · Sales during 2002 increased by 17 percent to SEK 129.7 million (compared to SEK 110.7 million for 2001). · Sales during the fourth quarter of 2002 amounted to SEK 30.2 million (compared to SEK 32.9 million for the fourth quarter of 2001). ·

A new indication for EmdogainGel approved in EU

A new indication for EmdogainGel approved in EU Biora has received European Union approval for a new indication for EmdogainGel in the treatment of recession defects (exposed root surfaces). Biora plans to launch this new indication in April, 2003. Donna Janson, CEO and President of Biora comments: " The recent approval within the European Union for the use of EmdogainGel in the treatment of recession defects demonstrates the expanding role of biology-based products in dental applications. Aesthetic soft tissue procedures are common in the United States and it is Biora´s belief that the

Biora - Report for the first nine months of 2002

Report for the first nine months of 2002 Biora AB (publ) November 7, 2002 3rd Qtr 3rd Qtr 1- Qtr 1- Full 2002 Qtr 3 3 2001 year 2001 2002 2001 Net sales, SEK million 28.1 22.0 99.5 77.8 110.7 Operating result, SEK million -1.7 -11.5 -1.3 -26.7 -26.5 Net result, SEK million -1.2 -11.0 -0.5 -25.7 -25.1 · Sales during the first nine months of 2002 increased by 28 percent to SEK 99.5 million (compared to SEK 77.8 million for the first nine months of 2001). · Sales during the third quarter of 2002 increased by 28 percent to SEK 28.1 million (compared to SEK 22.0 million for the third quarter of

Biora - Report for the first half of 2002

Report for the first half of 2002 Biora AB (publ) August 23, 2002 2nd Qtr 2nd First First Full 2002 Qtr half half year 2001 2002 2001 2001 Net sales, SEK million 36.4 28.8 71.4 55.8 110.7 Operating result, SEK million 1.4 -6.2 0.4 -15.2 -26.5 Net result, SEK million 1.4 -6.1 0.7 -14.8 -25.1 * Sales during the first half of 2002 increased by 28 percent to SEK 71.4 million (compared to SEK 55.8 million for the first half of 2001). * Sales during the second quarter 2002 increased by 26 percent to SEK 36.4 million (compared to SEK 28.8 million for the second quarter 2001). The increase occurred

Biora AB appoints a new CFO

Biora AB appoints a new CFO Svante Lundell has been appointed as the new Chief Financial Officer of Biora AB effective September 1st 2002. He replaces Kerstin Pålsson who has decided to resign from her position as CFO of the Company due to family reasons. Ms. Pålsson joined Biora as Group Controller in 1997. Svante Lundell has held a number of executive financial positions in Sweden and Europe for US based companies throughout his career. He has most recently practiced as a financial consultant focusing on financial analysis. Prior to that, he was Vice President, Finance Europe at Hercules

Interim report

INTERIM REPORT January 1 - September 30 1998 * Sales: January 1 - September 30, SEK 35.4 million (compared to SEK 9.1 million for the same period in 1997). * Sales: July 1 - September 30, SEK 12.5 million. (compared to SEK 3.4 million for the same period in 1997). * Operating loss: SEK -41.5 million (compared to SEK -67.5 million for the same period in 1997) (operating loss for the nine months ended September 30, includes nonrecurring revenue from Biora's Japanese partner in an amount of SEK 39.4 million). * Loss after tax: SEK -32.2 million (compared to SEK -53.8 million for the same

Biora to Commence Sales in Mexico and Spain

Biora to Commence Sales in Mexico and Spain Malmö, Sweden, October 1, 1998 - Biora AB (Nasdaq: BIORY, SSE: BIOR) today announced that this week it will begin sales in Mexico through the distributor MediMix and in Spain through UEDA Española. Biora's principal product, ® Emdogain , is approved for marketing in Europe, the United States and Japan and the company is now gradually and progressively building its sales organizations in the respective countries. "Biora's strategy in the short term is to concentrate its marketing efforts on North America, Europe and Japan" commented Tomas

There are no items matching the current filter
There are no more items matching the current filter
Back to top